vs
Ibotta, Inc.（IBTA）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
Ibotta, Inc.的季度营收约是RIGEL PHARMACEUTICALS INC的1.3倍（$88.5M vs $69.8M），RIGEL PHARMACEUTICALS INC同比增速更快（21.2% vs -10.0%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 3.7%）
Ibotta, Inc.是总部位于美国科罗拉多州丹佛市的移动科技公司，成立于2011年，目前仅在美国开展业务。公司依托自主开发的Ibotta绩效网络与面向消费者的手机应用，为各类消费提供现金返现奖励，同时与快速消费品品牌及网络发行商合作，还推出了返现即服务业务。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
IBTA vs RIGL — 直观对比
营收规模更大
IBTA
是对方的1.3倍
$69.8M
营收增速更快
RIGL
高出31.2%
-10.0%
两年增速更快
RIGL
近两年复合增速
3.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $88.5M | $69.8M |
| 净利润 | — | $268.1M |
| 毛利率 | 78.7% | 91.5% |
| 营业利润率 | -1.9% | 33.2% |
| 净利率 | — | 384.0% |
| 营收同比 | -10.0% | 21.2% |
| 净利润同比 | — | 1769.2% |
| 每股收益（稀释后） | $-0.03 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IBTARIGL
| Q4 25 | $88.5M | $69.8M | ||
| Q3 25 | $83.3M | $69.5M | ||
| Q2 25 | $86.0M | $101.7M | ||
| Q1 25 | $84.6M | $53.3M | ||
| Q4 24 | $98.4M | $57.6M | ||
| Q3 24 | $98.6M | $55.3M | ||
| Q2 24 | $87.9M | $36.8M | ||
| Q1 24 | $82.3M | $29.5M |
净利润IBTARIGL
| Q4 25 | — | $268.1M | ||
| Q3 25 | $1.5M | $27.9M | ||
| Q2 25 | $2.5M | $59.6M | ||
| Q1 25 | $555.0K | $11.4M | ||
| Q4 24 | — | $14.3M | ||
| Q3 24 | $17.2M | $12.4M | ||
| Q2 24 | $-34.0M | $-1.0M | ||
| Q1 24 | $9.3M | $-8.2M |
毛利率IBTARIGL
| Q4 25 | 78.7% | 91.5% | ||
| Q3 25 | 79.4% | 93.2% | ||
| Q2 25 | 79.2% | 95.6% | ||
| Q1 25 | 79.8% | 91.7% | ||
| Q4 24 | 84.6% | 89.9% | ||
| Q3 24 | 87.7% | 85.5% | ||
| Q2 24 | 86.0% | 92.4% | ||
| Q1 24 | 87.2% | 93.1% |
营业利润率IBTARIGL
| Q4 25 | -1.9% | 33.2% | ||
| Q3 25 | 2.8% | 40.9% | ||
| Q2 25 | 1.4% | 60.1% | ||
| Q1 25 | -3.3% | 23.9% | ||
| Q4 24 | 13.2% | 28.9% | ||
| Q3 24 | 21.0% | 25.4% | ||
| Q2 24 | -24.6% | 1.2% | ||
| Q1 24 | 19.3% | -23.6% |
净利率IBTARIGL
| Q4 25 | — | 384.0% | ||
| Q3 25 | 1.8% | 40.2% | ||
| Q2 25 | 2.9% | 58.6% | ||
| Q1 25 | 0.7% | 21.5% | ||
| Q4 24 | — | 24.9% | ||
| Q3 24 | 17.5% | 22.5% | ||
| Q2 24 | -38.6% | -2.8% | ||
| Q1 24 | 11.3% | -27.9% |
每股收益（稀释后）IBTARIGL
| Q4 25 | $-0.03 | $14.11 | ||
| Q3 25 | $0.05 | $1.46 | ||
| Q2 25 | $0.08 | $3.28 | ||
| Q1 25 | $0.02 | $0.63 | ||
| Q4 24 | $3.04 | $0.82 | ||
| Q3 24 | $0.51 | $0.70 | ||
| Q2 24 | $-1.32 | $-0.06 | ||
| Q1 24 | $0.33 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $186.6M | $155.0M |
| 总债务越低越好 | $0 | $52.5M |
| 股东权益账面价值 | $287.7M | $391.5M |
| 总资产 | $525.9M | $513.6M |
| 负债/权益比越低杠杆越低 | 0.00× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资IBTARIGL
| Q4 25 | $186.6M | $155.0M | ||
| Q3 25 | $223.3M | $137.1M | ||
| Q2 25 | $250.5M | $108.4M | ||
| Q1 25 | $297.1M | $77.1M | ||
| Q4 24 | $349.3M | $77.3M | ||
| Q3 24 | $341.3M | $61.1M | ||
| Q2 24 | $317.9M | $49.1M | ||
| Q1 24 | $79.5M | $49.5M |
总债务IBTARIGL
| Q4 25 | $0 | $52.5M | ||
| Q3 25 | — | $60.0M | ||
| Q2 25 | — | $60.0M | ||
| Q1 25 | — | $60.0M | ||
| Q4 24 | $0 | $60.0M | ||
| Q3 24 | $0 | $60.0M | ||
| Q2 24 | $0 | $60.0M | ||
| Q1 24 | $65.3M | $60.0M |
股东权益IBTARIGL
| Q4 25 | $287.7M | $391.5M | ||
| Q3 25 | $329.6M | $117.6M | ||
| Q2 25 | $354.1M | $81.9M | ||
| Q1 25 | $401.3M | $18.6M | ||
| Q4 24 | $457.3M | $3.3M | ||
| Q3 24 | $378.0M | $-14.6M | ||
| Q2 24 | $359.7M | $-29.9M | ||
| Q1 24 | $44.1M | $-31.7M |
总资产IBTARIGL
| Q4 25 | $525.9M | $513.6M | ||
| Q3 25 | $569.4M | $242.5M | ||
| Q2 25 | $600.8M | $206.7M | ||
| Q1 25 | $639.3M | $176.0M | ||
| Q4 24 | $678.4M | $164.0M | ||
| Q3 24 | $598.3M | $139.4M | ||
| Q2 24 | $556.0M | $128.4M | ||
| Q1 24 | $322.1M | $126.5M |
负债/权益比IBTARIGL
| Q4 25 | 0.00× | 0.13× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.73× | ||
| Q1 25 | — | 3.23× | ||
| Q4 24 | 0.00× | 18.25× | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 1.48× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.8M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $20.3M | — |
| 自由现金流率自由现金流/营收 | 22.9% | — |
| 资本支出强度资本支出/营收 | 8.5% | — |
| 现金转化率经营现金流/净利润 | — | 0.08× |
| 过去12个月自由现金流最近4个季度 | $75.0M | — |
8季度趋势，按日历期对齐
经营现金流IBTARIGL
| Q4 25 | $27.8M | $22.0M | ||
| Q3 25 | $21.8M | $24.0M | ||
| Q2 25 | $25.9M | $30.5M | ||
| Q1 25 | $19.9M | $-893.0K | ||
| Q4 24 | $22.0M | $14.5M | ||
| Q3 24 | $39.5M | $21.7M | ||
| Q2 24 | $35.0M | $302.0K | ||
| Q1 24 | $19.4M | $-5.0M |
自由现金流IBTARIGL
| Q4 25 | $20.3M | — | ||
| Q3 25 | $14.5M | — | ||
| Q2 25 | $22.2M | — | ||
| Q1 25 | $18.0M | — | ||
| Q4 24 | $21.8M | — | ||
| Q3 24 | $39.2M | — | ||
| Q2 24 | $34.8M | — | ||
| Q1 24 | $19.2M | — |
自由现金流率IBTARIGL
| Q4 25 | 22.9% | — | ||
| Q3 25 | 17.4% | — | ||
| Q2 25 | 25.8% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 22.1% | — | ||
| Q3 24 | 39.8% | — | ||
| Q2 24 | 39.6% | — | ||
| Q1 24 | 23.3% | — |
资本支出强度IBTARIGL
| Q4 25 | 8.5% | — | ||
| Q3 25 | 8.7% | — | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | 0.2% | — |
现金转化率IBTARIGL
| Q4 25 | — | 0.08× | ||
| Q3 25 | 14.19× | 0.86× | ||
| Q2 25 | 10.38× | 0.51× | ||
| Q1 25 | 35.78× | -0.08× | ||
| Q4 24 | — | 1.01× | ||
| Q3 24 | 2.29× | 1.75× | ||
| Q2 24 | — | — | ||
| Q1 24 | 2.08× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IBTA
| Redemption Revenue | $78.5M | 89% |
| Ad Other Revenue | $10.0M | 11% |
| Breakage | $2.1M | 2% |
RIGL
暂无分部数据
